All In Biotech

Drug Trial Radar · NCT06878365

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

Single-arm Open-label Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BI 3000202 in Adult Patients With Selected Type 1 Interferonopathies

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

16

Actual

Start

Jul 29, 2025

Primary completion

Dec 10, 2029

Study completion Dec 20, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with selected type 1 interferonopathies. People can join the study if they have Aicardi-Goutières syndrome (AGS), Coatomer subunit alpha (COPA) syndrome, Familial chilblain lupus (FCL), or another type 1 interferonopathy with a specific gene mutation. The purpose of this study is to find out how BI 3000202 is tolerated in people with selected type 1 interferonopathies. Participants take a lower dose of BI 3000202 as tablets for 4 weeks. Afterwards, they take a higher dose of BI 3000202 as tablets for 36 weeks. They may continue with the study treatment until every participant has completed 40 weeks of treatment (about 9 months). The participants may also continue their regular treatment for their condition during the study. During this study, participants visit the study site 13 times or more, depending on when they start their participation. The doctors check the health of the participants and note any health problems that could have been caused by BI 3000202.

Conditions

  • Type 1 Interferonopathies

Interventions

  • BI 3000202_low doseDrug

    BI 3000202\_low dose

  • BI 3000202_high doseDrug

    BI 3000202\_high dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of any treatment-emergent adverse events assessed as related to study drugTime frame: Approximately 72 weeks

Locations

20 sites in 9 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Texas Children's Hospital

    Houston, Texas

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Hôpital Gui de Chauliac

    Montpellier, France

  • Hopital Necker

    Paris, France

  • HOP Tenon

    Paris, France

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Barzilai Medical Center

    Ashkelon, Israel

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy

  • Azienda Sanitaria Universitaria Giuliano Isontina

    Trieste, Italy

  • ULS de Santa Maria, E.P.E - Hospital de Santa Maria

    Lisbon, Portugal

  • ULS de Santo Antônio, E.P.E - Centro Hospitalar Universitário de Santo António

    Porto, Portugal

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Royal Infirmary of Edinburgh

    Edinburgh, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.